## **Supplementary Online Content**

Kim H-H, Han K-U, Kim M-C, et al; Korean Laparoendoscopic Gastrointestinal Surgery Study Group. Effect of laparoscopic distal gastrectomy vs open distal gastrectomy on longterm survival among patients with stage 1 gastric cancer: the KLASS-1 randomized clinical trial. *JAMA Oncol.* Published online February 7, 2019. doi:10.1001/jamaoncol.2018.6727

**eTable.** Comparison of causes of death and recurrence patterns for patients included in the perprotocol population

eFigure 1. Kaplan-Meier survival curves for patients included in the final analysis in the per-


protocol population


eFigure 2. Post hoc subgroup analysis for overall survival

This supplementary material has been provided by the authors to give readers additional information about their work.

	LDG (n=644)	ODG (n=611)	Р
Total deaths - no.			0.526
Gastric cancer-related	24	24	
Other malignancy-related	8	8	
Others	32	30	
Unknown	7	14	
Total recurrence - no.			0.518
Locoregional	9	5	
Hematogenous	11	11	
Peritoneal	8	5	
Distant lymph node	1	3	
Mixed	6	5	

eTable. Comparison of causes of death and recurrence patterns in the per-protocol population





A, Overall survival was similar between the laparoscopic group and the open group (log-rank P = 0.392). B, Cancer-specific survival was also similar (log-rank P = 0.814). The median follow-up of patients was 99.8 months in all groups.

Baseline	Laparoscopic Open   gastrectomy gastrectomy   No. of event / Total No. of patients		Hazard Ratio for Death	<i>P</i> Value for interaction
Characteristic			(95% Confidence Interval)	
Age				0.48
<60 years	28/387	22/359	⊢ <del>i</del> ● −1	
≥60 years	51/286	63/327	<b>⊢</b> •	
Sex				0.47
Female	17/225	22/228	<b>⊢⊢</b>	
Male	62/448	63/458	<b>⊢ →</b> -1	
Body-mass index				0.09
<20.0 kg/m <sup>2</sup>	8/65	15/70	<b>⊢−</b> 1	
20.0-24.9 kg/m <sup>2</sup>	43/370	52/385	<b>⊢_</b> ● <mark>-</mark> -1	
≥25.0 kg/m²	28/238	18/231	<u>⊢</u> ∔	
Tumor size				0.28
<2.7 cm	44/392	41/400	<b>⊢</b> ↓● -1	
≥2.7 cm	34/268	43/276	<b>⊢</b> _● <u>+</u> 1	
Histologic type				0.97
Differentiated	68/515	76/538	<b>⊢</b>	
Undifferentiated	7/131	7/131	<b>⊢</b> −−−−1	
Others	2/18	1/11		•
Clinical T stage				0.41
T1	55/545	53/550	<b>⊢</b>	
T2	24/128	32/136	<b>⊢</b> ● - 1	
Clinical N stage				0.72
NO	77/658	83/667	⊢ <b>.</b>	
N1	2/15	2/19		• 1
Pathologic T stage				0.15
T1	51/548	45/549		
≥T2	27/124	40/137	<b>⊢●</b> →1	
Pathologic N stage				0.61
NO	55/571	55/571		
N+	23/101	30/115		
Tumor size				0.43
<3.0	45/423	44/430	↓ <b>●</b> _↓	0.540.557
>3.0	33/237	40/246		
Tumor size				0.76
<2.0	23/241	21/226		
≥2.0	55/419	63/450		
22.0	33/413	00/400		

eFigure 2. Post-hoc subgroup analysis for overall survival.

HR denotes hazard ratio and CI confidence interval. The figure shows *P* values for interactions and HRs for death in the laparoscopic group, with 95% CIs.

\* Data missing for 23 patients.

† Data missing for 15 patients who had unknown histologic type.

‡ Data missing for 1 patient who underwent laparoscopic biopsy for peritoneal seeding nodule biopsy.

© 2019 American Medical Association. All rights reserved.